MX337687B - Linea celular de amniocitos humanos permanente para la produccion de virus de influenza. - Google Patents

Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.

Info

Publication number
MX337687B
MX337687B MX2013001772A MX2013001772A MX337687B MX 337687 B MX337687 B MX 337687B MX 2013001772 A MX2013001772 A MX 2013001772A MX 2013001772 A MX2013001772 A MX 2013001772A MX 337687 B MX337687 B MX 337687B
Authority
MX
Mexico
Prior art keywords
cell lines
influenza viruses
permanent human
human amniocyte
producing influenza
Prior art date
Application number
MX2013001772A
Other languages
English (en)
Other versions
MX2013001772A (es
Inventor
Gudrun Schiedner
Udo Reichl
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of MX2013001772A publication Critical patent/MX2013001772A/es
Publication of MX337687B publication Critical patent/MX337687B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un método para producir una vacuna que tiene como base un virus de influenza mediante células de amniocitos humanos permanentes, así como al uso de una célula de amniocitos humanos permanente para la producción de una vacuna que tiene como base un virus de influenza.
MX2013001772A 2010-08-16 2011-08-16 Linea celular de amniocitos humanos permanente para la produccion de virus de influenza. MX337687B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010037008 2010-08-16
DE102011050353 2011-05-13
PCT/DE2011/075194 WO2012041311A1 (de) 2010-08-16 2011-08-16 Permanente humane amniozyten zelllinie zur herstellung von influenzaviren

Publications (2)

Publication Number Publication Date
MX2013001772A MX2013001772A (es) 2013-06-03
MX337687B true MX337687B (es) 2016-03-15

Family

ID=44936126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001772A MX337687B (es) 2010-08-16 2011-08-16 Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.

Country Status (19)

Country Link
US (1) US20130344569A1 (es)
EP (1) EP2606128B1 (es)
JP (1) JP5928843B2 (es)
KR (1) KR101780257B1 (es)
CN (1) CN103168100B (es)
AU (1) AU2011307655B2 (es)
BR (1) BR112013003766B1 (es)
CA (1) CA2808453C (es)
DE (1) DE112011102737A5 (es)
DK (1) DK2606128T3 (es)
ES (1) ES2524894T3 (es)
IL (1) IL224728A (es)
MX (1) MX337687B (es)
PL (1) PL2606128T3 (es)
PT (1) PT2606128E (es)
RU (1) RU2565546C2 (es)
SG (1) SG187863A1 (es)
TW (1) TW201211257A (es)
WO (1) WO2012041311A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
AU2005322353B2 (en) * 2004-12-23 2011-09-01 Medimmune, Llc Non-tumorigenic MDCK cell line for propagating viruses
EP2614836A3 (en) * 2005-10-17 2013-10-23 MedImmune, LLC High growth reassortant influenza A virus
DE102005054628A1 (de) * 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
RU2487935C2 (ru) * 2006-09-15 2013-07-20 Медиммун, Ллк. Линии клеток почки собаки майдин-дэрби (mdck), поддерживающие рост вирусов до высоких титров, и способ применения этих клеток в биореакторе

Also Published As

Publication number Publication date
RU2565546C2 (ru) 2015-10-20
EP2606128B1 (de) 2014-09-10
SG187863A1 (en) 2013-03-28
KR20130097191A (ko) 2013-09-02
IL224728A (en) 2016-05-31
CA2808453A1 (en) 2012-04-05
KR101780257B1 (ko) 2017-09-21
DK2606128T3 (en) 2014-12-01
CN103168100B (zh) 2016-04-13
PT2606128E (pt) 2014-12-09
WO2012041311A1 (de) 2012-04-05
TW201211257A (en) 2012-03-16
CA2808453C (en) 2020-05-05
EP2606128A1 (de) 2013-06-26
US20130344569A1 (en) 2013-12-26
JP2013537543A (ja) 2013-10-03
ES2524894T3 (es) 2014-12-15
RU2013110786A (ru) 2014-09-27
BR112013003766B1 (pt) 2021-08-24
CN103168100A (zh) 2013-06-19
BR112013003766A2 (pt) 2016-05-31
PL2606128T3 (pl) 2015-02-27
AU2011307655A1 (en) 2013-03-21
MX2013001772A (es) 2013-06-03
AU2011307655B2 (en) 2015-12-17
DE112011102737A5 (de) 2013-06-06
JP5928843B2 (ja) 2016-06-01

Similar Documents

Publication Publication Date Title
HRP20181422T1 (hr) Mdck-derivirane stanične linije prilagođene kulturi bez seruma i suspenzijskoj kulturi te postupak proizvodnje virusa cjepiva koristeći navedene stanice
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
EA201300915A1 (ru) Новый европейский штамм prrsv
MX2013001045A (es) Organoide hepatico, sus usos y metodo de cultivo para obtenerlos.
EP2940255A4 (en) SYSTEM AND METHOD FOR GENERATING ELECTRICITY
MX349119B (es) Vacuna de virus de dengue inactivado.
SG11201404570WA (en) Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
EP2600461A4 (en) BIPOLAR ELECTRODE, BIPOLAR SECONDARY BATTERY COMPRISING SAME, AND METHOD FOR PRODUCING BIPOLAR ELECTRODE
MX359769B (es) Metodos para descelularizar huesos.
EP2801611A4 (en) MICRO-ORGANISM FOR THE PRODUCTION OF L-AMINO ACID AND PROCESS FOR THE PRODUCTION OF L-AMINO ACIDS THEREWITH
EP2659969A4 (en) OPTICAL SEMICONDUCTOR AND ITS MANUFACTURING METHOD, AND OPTICAL SEMICONDUCTOR DEVICE, PHOTOCATALYST, HYDROGEN GENERATION DEVICE, AND ENERGY LINE
GB2518305A (en) Energy Harvesting System
EP2940259A4 (en) POWER GENERATION SYSTEM AND MAINTENANCE PROCESS FOR THE POWER GENERATION SYSTEM
SG10201808644PA (en) Recombinant mycobacterium as a vaccine
WO2013052095A3 (en) Vaccine
IN2013MN00733A (es)
EP2573168A4 (en) METHODS FOR PRODUCING NERVE CELLS FROM STEM CELLS, NERVE CELLS, AND USES THEREOF
EP2892555A4 (en) NEUTRALIZING HIV-1 ANTIBODY IMMUNOGENS, METHODS OF GENERATION AND USES THEREOF
IN2014DE01009A (es)
MX2015002495A (es) Rotavirus humanos modificados y usos para estos.
MX360120B (es) Produccion de virus infecciosos de influenza.
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
MX337687B (es) Linea celular de amniocitos humanos permanente para la produccion de virus de influenza.
MX2015007195A (es) Preparacion de vacunas vivas.
EP2501405A4 (en) COMPOSITION, METHOD, AND USES OF POX VIRUS ELEMENTS IN VACCINATE CONSTRUCTS

Legal Events

Date Code Title Description
FG Grant or registration